Ad
related to: dr reddy's usa
Search results
Results From The WOW.Com Content Network
The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed.They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". [8]
Dr. Reddy's Finasteride Tablets 1 mg is available in bottle counts of 30 and 90. Disclaimer This press release includes forward-looking statements, as defined in the U.S. Private Securities ...
About Dr. Reddy's Dr. Reddy's Laboratories Ltd. ( NYS: RDY ) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
In the early 1980s, Reddy founded Desert Valley Medical Group in Victorville, CA and established Primecare Medical Group in 1992. He also founded PrimeRx, with 250,000 managed care patients, generating over $500 million in revenues a headquartered in Las Vegas, Nevada.
Kallam Satish Reddy is an Indian business executive and current Chairman of Dr. Reddy's Laboratories. [ 2 ] [ 3 ] Reddy joined Dr. Reddy's Laboratories in 1993 as executive director. Elevated to the role of Managing Director in 1997, he led the company's transition from a manufacturer of active pharmaceutical ingredients to one with a diverse ...
In 2007, the Los Angeles Times ran a news story that alleged that the policies of Prime HealthCare Services, Inc., resulted in higher-than-average profits for the possible cost of patient care: "When Reddy's company, Prime Healthcare Services Inc., takes over a hospital, it typically cancels insurance contracts, allowing the hospital to collect ...
Reddy, a Johnson County physician seeking to oust Davids, a three-term incumbent in Kansas’ 3rd Congressional District, hit Davids over inflation he said was fueled by federal spending.
In 2018, [22] and 2019, [23] Aurobindo Pharma USA recalled tablets containing valsartan due to the detection of N-Nitrosodiethylamine (NDEA) which is a probable human carcinogen. In November 2019, Aurobindo Pharma USA recalled ranitidine tablets, capsules, and syrup due to the detection of unacceptable levels of N-nitrosodimethylamine (NDMA).